Alexander E. Drilon, MD

home / authors / alexander-e-drilon-md

Articles

Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLC

April 25th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.

Dr. Drilon on Rare Drivers in NSCLC

Alexander E. Drilon, MD

February 15th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses rare drivers in non–small cell lung cancer (NSCLC).

Dr. Drilon Discusses the Adoption of NGS in Lung Cancer

Alexander E. Drilon, MD

February 8th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses the adoption of next-generation sequencing (NGS) in lung cancer.

Dr. Drilon on Tepotinib and Gefitinib in MET+ EGFR-Mutant NSCLC

Alexander E. Drilon, MD

November 15th 2018

Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).